Free tool
FAERS Monitor: Intrarosa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208470 or its brand name (Intrarosa, Prasterone). Reports on generic versions are filed under their own applications.
Reports
2,752
Serious
892
32% of reports
Hospitalization
294
Death reported
47
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use803
- fatigue171
- headache171
- drug ineffective168
- nausea132
- product dose omission issue130
- application site discharge115
- rash95
- dizziness94
- insomnia93
- pain92
- vaginal discharge85
- alopecia81
- pruritus81
- vulvovaginal burning sensation80
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 4 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 11 |
| 2011 | 35 |
| 2012 | 58 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 10 |
| 2016 | 19 |
| 2017 | 24 |
| 2018 | 312 |
| 2019 | 441 |
| 2020 | 301 |
| 2021 | 209 |
| 2022 | 258 |
| 2023 | 300 |
| 2024 | 228 |
| 2025 | 291 |
| 2026 | 228 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,407 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site dischargeSignal | 115 | 846.7 | 700.9 | 86,702 |
| vulvovaginal burning sensationSignal | 80 | 101.5 | 81.7 | 7,759 |
| vaginal dischargeSignal | 85 | 64.7 | 52.4 | 5,227 |
| off label useSignal | 803 | 7.0 | 6.6 | 4,311 |
| product dose omission issueSignal | 130 | 3.4 | 2.9 | 218 |
| alopeciaSignal | 81 | 3.2 | 2.5 | 118 |
| insomniaSignal | 93 | 2.7 | 2.2 | 97 |
| headacheSignal | 171 | 2.1 | 1.8 | 98 |
| fatigue | 171 | 1.7 | 1.5 | 48 |
| rash | 95 | 1.7 | 1.4 | 25 |
| pruritus | 81 | 1.6 | 1.3 | 18 |
| dizziness | 94 | 1.4 | 1.2 | 13 |
| nausea | 132 | 1.3 | 1.1 | 8 |
| pain | 92 | 1.1 | 0.9 | 2 |
| drug ineffective | 168 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.